1 |
cytotoxic T-lymphocyte-associated protein 4
(1661 times)
|
Neoplasms (423 times)
|
PD-1 (394 times) PD-L1 (248 times) ICIs (126 times)
|
1995 Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
|
2 |
cytotoxic T-lymphocyte antigen-4
(1286 times)
|
Neoplasms (294 times)
|
PD-1 (256 times) PD-L1 (136 times) ICIs (78 times)
|
1995 Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
|
3 |
CTL-associated antigen 4
(28 times)
|
Neoplasms (15 times)
|
CTLs (3 times) TME (3 times) DC (2 times)
|
2004 CTLA-4-dependent mechanisms prevent T cell induced-liver pathology during the erythrocyte stage of Plasmodium berghei malaria.
|
4 |
cytotoxic T cell antigen 4
(14 times)
|
Neoplasms (3 times)
|
OR (3 times) PD-1 (2 times) SNPs (2 times)
|
2003 Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
|
5 |
CTL antigen 4
(13 times)
|
Neoplasms (11 times)
|
PD-1 (3 times) PD-L1 (2 times) CR (1 time)
|
2003 Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.
|
6 |
CTL-associated protein 4
(6 times)
|
Allergy and Immunology (3 times)
|
TIM-3 (3 times) BTLA (2 times) IC (2 times)
|
2009 Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.
|
7 |
anti-CTL antigen-4
(4 times)
|
Neoplasms (4 times)
|
mAb (2 times) PD-1 (2 times) GITR (1 time)
|
2006 Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
|
8 |
cytotoxic T lymphocyte Ag-4
(3 times)
|
Allergy and Immunology (2 times)
|
ICI (1 time) irAE (1 time) SEB (1 time)
|
1997 Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
|
9 |
cytotoxic T-cell associated protein-4
(3 times)
|
Neoplasms (2 times)
|
PD-1 (3 times) PD-L1 (2 times) CRC (1 time)
|
2019 Modulation of immune checkpoint molecule expression in mantle cell lymphoma.
|
10 |
anti-cytotoxic T-lymphocyte 4
(2 times)
|
Allergy and Immunology (1 time)
|
ICI (1 time) IL (1 time) IMDC (1 time)
|
2017 Immune correlates of clinical outcome in melanoma.
|
11 |
cell lymphocyte-associated molecule-4
(2 times)
|
Genetics (1 time)
|
ATD (1 time) HT (1 time) TRAb (1 time)
|
2002 Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
|
12 |
anti-cytotoxic T-cell-associated protein-4
(1 time)
|
Neoplasms (1 time)
|
CI (1 time) FDA (1 time) ICI (1 time)
|
2022 Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
|
13 |
anti-cytotoxic T-lymphocyte antigen-4 monoclonal
(1 time)
|
Neoplasms (1 time)
|
---
|
2014 An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
|
14 |
case of autoimmune hypophysitis induced by the anticytotoxic T-lymphocyte antigen-4
(1 time)
|
Endocrinology (1 time)
|
irAE (1 time)
|
2015 Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.
|
15 |
CD28 lead to signaling activation, while T-lymphocyte antigen 4
(1 time)
|
Allergy and Immunology (1 time)
|
PD-1 (1 time) PI3K (1 time)
|
2021 Molecular interactions of the CTLA-4 cytoplasmic region with the phosphoinositide 3-kinase SH2 domains.
|
16 |
change in the levels of T-lymphocyte-associated antigen 4
(1 time)
|
Neurosurgery (1 time)
|
ELISA (1 time) GKR (1 time) PD-L1 (1 time)
|
2019 Gamma knife radiosurgery compared to whole brain radiation therapy enhances immunity via immunoregulatory molecules in patients with metastatic brain tumours.
|
17 |
checkpoint inhibitors, namely anticytotoxic T-lymphocyte antigen-4
(1 time)
|
|
ACTH (1 time) MRI (1 time) NSCLC (1 time)
|
2018 Two Cases of Atezolizumab-Induced Hypophysitis.
|
18 |
clarify the role of the T-lymphocyte-associated-4
(1 time)
|
Endocrinology (1 time)
|
Ab (1 time) AITD (1 time) RFLP (1 time)
|
2003 Association of the CTLA-4 gene 49 A/G polymorphism with type 1 diabetes and autoimmune thyroid disease in Japanese children.
|
19 |
combinations of the following monoclonal antibodies: CD3-PE/cy5, CD4-APC, CD8-APC, CD152-PE
(1 time)
|
Medicine (1 time)
|
CHB (1 time) PBMCs (1 time) PD-L1 (1 time)
|
2013 CTLA-4 and its ligands on the surface of T- and B-lymphocyte subsets in chronic hepatitis B virus infection.
|
20 |
common T lymphocyte antigen 4
(1 time)
|
Drug Therapy (1 time)
|
PD-1 (1 time)
|
2015 The genetic basis of new treatment modalities in melanoma.
|
21 |
CONTENT: T-lymphocyte-associated antigen 4
(1 time)
|
Communicable Diseases (1 time)
|
ESCMID (1 time) ESGICH (1 time) mAb (1 time)
|
2018 ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
|
22 |
cytokine suppressors such as T lymphocyte-associated antigen-4
(1 time)
|
Complementary Therapies (1 time)
|
ELISA (1 time) ICOS (1 time) IFN-gamma (1 time)
|
2012 Repressor of GATA-3 can negatively regulate the expression of T cell cytokines through modulation on inducible costimulator.
|
23 |
cytotoxic T cell associated antigen-4
(1 time)
|
Chemistry (1 time)
|
MAPK (1 time) MEK (1 time) PD-L1 (1 time)
|
2020 Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
|
24 |
cytotoxic T-cell-associated Ag-4
(1 time)
|
Cells (1 time)
|
BM-MSCs (1 time) DT-MSCs (1 time) GVHD (1 time)
|
2019 Mesenchymal Stem/Stromal Cells Derived from Dental Tissues: A Comparative In Vitro Evaluation of Their Immunoregulatory Properties Against T cells.
|
25 |
cytotoxic T-lymphocyte attenuator-4
(1 time)
|
Communicable Diseases (1 time)
|
LAG-3 (1 time) PD-1 (1 time)
|
2015 Induction of Inhibitory Receptors on T Cells During Plasmodium vivax Malaria Impairs Cytokine Production.
|